# CF 3: Clinical Trials & Advocacy Core

> **NIH NIH P50** · SLOAN-KETTERING INST CAN RESEARCH · 2021 · $64,885

## Abstract

CF-3: Clinical Trials and Advocacy Core
ABSTRACT
 Sarcomas are a rare and heterogeneous group of malignancies of mesenchymal origin that affect
individuals of all ages. Sarcomas portend a poor prognosis with an estimated three-year survival rate of
20% for patients with metastatic disease. Treatments for patients with sarcoma have greatly lagged
behind those available for the epithelial and hematopoietic malignancies. Sarcoma therefore represents
an area of unmet potential in which there is a tremendous need for preclinical and clinical advancement.
Clinical research on sarcoma presents unique challenges that are inherent to serving a rare patient
population with each disease subtype having a unique biologic, pathogenic, genetic, and epigenetic basis
that can be characterized and therapeutically exploited. The conduct of clinical trials on sarcoma is a
labor-intensive undertaking that requires specific attention, initiatives, infrastructure, and expertise,
apart from and in addition to those of any major cancer center.
 The main objective of the Clinical Trials and Advocacy Core (CF-3) is to support the translational
and clinical efforts of the MSKCC SPORE in Soft Tissue Sarcoma. The CF-3 will be jointly run by key
members of the adult and pediatric sarcoma programs at Memorial Sloan Kettering Cancer Center
(MSKCC), ensuring the fluid application of novel therapies across all age groups. The CF-3 will bridge
the adult and pediatric sarcoma programs at MSKCC; the basic science, translational, and clinical aspects
of the various SPORE projects; and the Administrative, Biostatistical, and Biospecimen Cores.
Additionally, the CF-3 will facilitate seamless clinical collaboration with other Sarcoma SPOREs,
cooperative/government funding mechanisms for clinical trials (ETCTN/Cancer Therapy Evaluation
Program [CTEP]/Alliance), pharmaceutical companies, advocacy groups, and immune and
developmental therapeutic programs. The CF-3 will provide SPORE investigators with expertise in
clinical trial development and administration, support staff for the clinical trials, expertise in and
administration of clinical trial correlates, financial support for conducting clinical trials and performing
correlative studies, and mechanisms for developing and acquiring novel therapies for rare diseases. The
CF-3, in close collaboration with the other SPORE cores, will provide the much-needed infrastructure to
ensure that the translational mission of the SPORE is realized across age groups in a timely, cost-
effective, and cooperative manner.
 CF-3 will work to facilitate the engagement and involvement of minority participants in our
clinical research. CF-3 will also develop a program to involve patient advocacy and support groups, with
the goal of developing our clinical trial protocols to best serve the needs of the patients. This aim will
also have an educational component, which will allow for conversations between the MSKCC Sarcoma
Disease Management Team and patients, ...

## Key facts

- **NIH application ID:** 10247695
- **Project number:** 5P50CA217694-04
- **Recipient organization:** SLOAN-KETTERING INST CAN RESEARCH
- **Principal Investigator:** William D. Tap
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $64,885
- **Award type:** 5
- **Project period:** 2018-09-01 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10247695

## Citation

> US National Institutes of Health, RePORTER application 10247695, CF 3: Clinical Trials & Advocacy Core (5P50CA217694-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10247695. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*